Merus NVNASDAQ:MRUS
- LAST PRICE51.1900
- TODAY'S CHANGE (%)-0.0400 (-0.0781%)
- Bid / Lots51.0900/ 7
- Ask / Lots51.2900/ 7
- Open / Previous Close48.9100 / 51.2300
- Day Range
- 52 Week Range
- Volume100,369
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MRUS |
|---|---|---|
| 09:32 ET | 8402 | 49 |
| 09:33 ET | 1958 | 49 |
| 09:35 ET | 3660 | 49 |
| 09:37 ET | 3840 | 50.655 |
| 09:39 ET | 200 | 50.99 |
| 09:42 ET | 300 | 50.5963 |
| 09:46 ET | 600 | 50.985 |
| 09:48 ET | 300 | 51.18 |
| 09:50 ET | 800 | 51.195 |
| 09:51 ET | 2100 | 50.85 |
| 09:53 ET | 100 | 50.965 |
| 09:57 ET | 400 | 51.11 |
| 10:00 ET | 1162 | 50.94 |
| 10:02 ET | 100 | 51.12 |
| 10:04 ET | 600 | 51.28 |
| 10:06 ET | 300 | 51.225 |
| 10:08 ET | 418 | 51.195 |
| 10:11 ET | 1999 | 51 |
| 10:18 ET | 200 | 50.99 |
| 10:20 ET | 900 | 50.88 |
| 10:22 ET | 100 | 50.88 |
| 10:26 ET | 400 | 50.8725 |
| 10:27 ET | 200 | 50.93 |
| 10:29 ET | 1000 | 50.87 |
| 10:31 ET | 726 | 50.96 |
| 10:40 ET | 346 | 50.845 |
| 10:42 ET | 400 | 50.99 |
| 10:44 ET | 200 | 50.965 |
| 10:45 ET | 200 | 51.11 |
| 10:47 ET | 100 | 51.29 |
| 10:49 ET | 1870 | 51.37 |
| 10:51 ET | 300 | 51.38 |
| 10:54 ET | 375 | 51.49 |
| 10:56 ET | 100 | 51.38 |
| 10:58 ET | 560 | 51.45 |
| 11:00 ET | 200 | 51.46 |
| 11:02 ET | 417 | 51.65 |
| 11:03 ET | 1609 | 51.245 |
| 11:09 ET | 193 | 51.49 |
| 11:12 ET | 700 | 51.365 |
| 11:16 ET | 1565 | 51.335 |
| 11:18 ET | 300 | 51.51 |
| 11:20 ET | 100 | 51.61 |
| 11:21 ET | 100 | 51.56 |
| 11:23 ET | 400 | 51.65 |
| 11:25 ET | 100 | 51.7 |
| 11:27 ET | 500 | 51.7 |
| 11:30 ET | 300 | 51.46 |
| 11:34 ET | 100 | 51.475 |
| 11:36 ET | 4964 | 51.62 |
| 11:38 ET | 200 | 51.52 |
| 11:41 ET | 400 | 51.7 |
| 11:43 ET | 200 | 51.74 |
| 11:45 ET | 100 | 51.61 |
| 11:48 ET | 600 | 51.41 |
| 11:50 ET | 1700 | 51.4 |
| 11:52 ET | 100 | 51.4 |
| 11:59 ET | 1100 | 51.405 |
| 12:01 ET | 100 | 51.375 |
| 12:03 ET | 844 | 51.5 |
| 12:06 ET | 900 | 51.45 |
| 12:10 ET | 493 | 51.41 |
| 12:24 ET | 965 | 51.37 |
| 12:26 ET | 200 | 51.37 |
| 12:30 ET | 200 | 51.44 |
| 12:32 ET | 400 | 51.35 |
| 12:39 ET | 100 | 51.37 |
| 12:44 ET | 1300 | 51.165 |
| 12:50 ET | 200 | 51.19 |
| 12:51 ET | 200 | 51.185 |
| 12:55 ET | 922 | 51.19 |
Today
DJ Merus: FDA Extends Review of Cancer Drug Zenocutuzumab to February, from 4 hours ago by Dow Jones
4 hours ago by Dow JonesMerus Receives FDA extension of PDUFA for zenocutuzumab, from 6 hours ago by Dow Jones
6 hours ago by Dow Jones
Nov 1, 2024
DJ Merus Price Target Maintained With a $85.00/Share by HC Wainwright & Co., from 7:24AM ET on Friday Nov 01, 2024 by Dow Jones
7:24AM ET on Friday Nov 01, 2024 by Dow JonesDJ Merus Price Target Maintained With a $85.00/Share by Needham, from 6:07AM ET on Friday Nov 01, 2024 by Dow Jones
6:07AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update, from 8:08AM ET on Thursday Oct 31, 2024 by Dow Jones
8:08AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Merus NV | 3.5B | -13.1x | --- |
Iovance Biotherapeutics Inc | 3.5B | -6.8x | --- |
Immunitybio Inc | 3.6B | -5.8x | --- |
Rhythm Pharmaceuticals Inc | 3.2B | -12.5x | --- |
Apogee Therapeutics Inc | 3.3B | -25.5x | --- |
Edgewise Therapeutics Inc | 3.2B | -22.9x | --- |
Company Information
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Contact Information
- Headquarters
- Uppsalalaan 17, 3rd & 4th floorUTRECHT, Netherlands 3584 CT
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Anand Mehra
- President, Chief Executive Officer, Executive Director
- Sven Lundberg
- Chief Financial Officer
- Gregory Perry
- Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
- Peter Silverman
- Chief Medical Officer
- Fabian Zohren
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5B |
|---|---|
Revenue (TTM) | $35.9M |
Shares Outstanding | 68.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-3.91 |
Book Value | $6.16 |
P/E Ratio | -13.1x |
Price/Sales (TTM) | 97.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -642.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
